Century Therapeutics Inc (IPSC) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Century Therapeutics Inc

NASDAQ | IPSC

0.46

USD

-0.0096 (-2.04%)

AT CLOSE (AS OF Apr 3, 2025)

$40M

MARKET CAP

P/E Ratio

-1.61

EPS

$4.4

52 Week High

$0.45

52 Week Low

LIFE SCIENCES

Sector

IPSC Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

IPSC Technicals

Tags:

IPSC Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-$31M
Total Revenue	$6.6M
Cost Of Revenue	$37M
Costof Goods And Services Sold	-
Operating Income	-$138M
Selling General And Administrative	$33M
Research And Development	$107M
Operating Expenses	$145M
Investment Income Net	-
Net Interest Income	$13M
Interest Income	$13M
Interest Expense	-
Non Interest Income	$6.6M
Other Non Operating Income	$354K
Depreciation	$13M
Depreciation And Amortization	$13M
Income Before Tax	-$125M
Income Tax Expense	$1.8M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$127M
Comprehensive Income Net Of Tax	-$126M
Ebit	-$138M
Ebitda	-$111M
Net Income	-$127M

Revenue & Profitability

Earnings Performance

IPSC Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$353M
Total Current Assets	$194M
Cash And Cash Equivalents At Carrying Value	$58M
Cash And Short Term Investments	$189M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$159M
Property Plant Equipment	$62M
Accumulated Depreciation Amortization Ppe	$36M
Intangible Assets	$34M
Intangible Assets Excluding Goodwill	$34M
Goodwill	-
Investments	$162M
Long Term Investments	$31M
Short Term Investments	$131M
Other Current Assets	$4.8M
Other Non Current Assets	-
Total Liabilities	$192M
Total Current Liabilities	$130M
Current Accounts Payable	$3.1M
Deferred Revenue	$109M
Current Debt	-
Short Term Debt	-
Total Non Current Liabilities	$62M
Capital Lease Obligations	$54M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$49M
Other Current Liabilities	$75K
Other Non Current Liabilities	$8.7M
Total Shareholder Equity	$161M
Treasury Stock	-
Retained Earnings	-$782M
Common Stock	$9K
Common Stock Shares Outstanding	$86M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$110M
Payments For Operating Activities	$501K
Proceeds From Operating Activities	-$3.4M
Change In Operating Liabilities	-$4.8M
Change In Operating Assets	-$543K
Depreciation Depletion And Amortization	$8.5M
Capital Expenditures	$154K
Change In Receivables	-
Change In Inventory	-
Profit Loss	-$127M
Cashflow From Investment	$47M
Cashflow From Financing	$75M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$141K
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$141K
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$127M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-$31M
Total Revenue	$6.6M
Cost Of Revenue	$37M
Costof Goods And Services Sold	-
Operating Income	-$138M
Selling General And Administrative	$33M
Research And Development	$107M
Operating Expenses	$145M
Investment Income Net	-
Net Interest Income	$13M
Interest Income	$13M
Interest Expense	-
Non Interest Income	$6.6M
Other Non Operating Income	$354K
Depreciation	$13M
Depreciation And Amortization	$13M
Income Before Tax	-$125M
Income Tax Expense	$1.8M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$127M
Comprehensive Income Net Of Tax	-$126M
Ebit	-$138M
Ebitda	-$111M
Net Income	-$127M

IPSC Profile

Century Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

None

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
LCID	$2.34	-2.30%	$7.67B	187,389,814
F	$9.68	-4.68%	$39.53B	173,285,336
PTIX	$0.43	91.50%	$4.04M	173,208,693

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
ABBV	$202.45	-1.34%	$364.89B	5,252,004
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669